Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Amoxicillin-Clavulanate vs Ampicillin
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.
Ampicillin is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Acute bacterial sinusitis,Acute otitis media,Community-acquired pneumonia,Urinary tract infections,Skin and skin structure infections,Intra-abdominal infections,Lower respiratory tract infections,Diabetic foot infections,Prophylaxis of infection following surgery (off-label)
Respiratory tract infections,Urinary tract infections,Meningitis,Septicemia,Endocarditis,Gastrointestinal infections,Intra-abdominal infections,Skin and soft tissue infections,Prophylaxis for bacterial endocarditis (off-label),Listeriosis
500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.
250-500 mg orally every 6 hours; 1-2 g IV/IM every 4-6 hours.
Amoxicillin: ~1-1.3 hours in adults with normal renal function; Clavulanate: ~1 hour. Both prolonged in renal impairment (amoxicillin up to 7-20 hours with Cr Cl <10 m L/min).
Terminal elimination half-life: 1-1.8 hours in adults with normal renal function; prolonged to 7-20 hours in end-stage renal disease (Cr Cl <10 m L/min).
Amoxicillin is partially metabolized via hydrolysis of the beta-lactam ring to inactive penicilloic acid, minor hepatic metabolism; excreted primarily unchanged renally. Clavulanate is extensively metabolized in the liver, primarily to metabolites excreted in urine and feces.
Ampicillin is primarily excreted unchanged in the urine via renal tubular secretion and glomerular filtration. A small portion is metabolized by hydrolysis to penicilloic acid, but hepatic metabolism is minimal.
Amoxicillin: ~60% renal as unchanged drug via glomerular filtration and tubular secretion; Clavulanate: ~30-50% renal as metabolites and unchanged, remainder fecal. Approximately 50-70% of total dose excreted renally within 6 hours.
Renal: 90% unchanged via glomerular filtration and tubular secretion; biliary: 10% (small amount).
Amoxicillin: ~17% bound to serum protein (primarily albumin); Clavulanate: ~25% bound to albumin.
17-20% bound to serum albumin.
Amoxicillin: Vd ~0.3-0.4 L/kg; clavulanate: Vd ~0.3 L/kg. Distributes well into interstitial fluid, tissues, and bone; limited CNS penetration (10-20% of serum levels) unless inflamed meninges.
0.28-0.31 L/kg (higher in neonates and critically ill patients).
Oral: 80-90% for both components; food does not significantly affect absorption (note: clavulanate is better absorbed with food, extended-release tab with food).
Oral: 50% (fasting); reduced by 25-50% with food. IM: ~100% (complete absorption).
Cr Cl 30-50 m L/min: 500 mg/125 mg orally every 12 hours; Cr Cl 10-29 m L/min: 500 mg/125 mg orally every 24 hours; Cr Cl <10 m L/min: 500 mg/125 mg orally every 24 hours, supplement after dialysis.
Cr Cl 10-50 m L/min: administer every 6-12 hours; Cr Cl <10 m L/min: administer every 12-24 hours.
No specific adjustment recommended; use with caution in severe hepatic impairment (Child-Pugh C).
No adjustment needed for hepatic impairment; dose as in normal hepatic function.
3 months to 40 kg: 25-45 mg/kg/day of amoxicillin component in 2-3 divided doses; >40 kg: adult dosing.
Neonates: 25-50 mg/kg IV/IM every 12 hours (first week), every 8 hours (1-4 weeks); Infants/Children: 25-100 mg/kg/day IV/IM divided every 6-8 hours; Oral: 50-100 mg/kg/day divided every 6-8 hours.
Adjust based on renal function; initiate with lower end of dosing due to age-related renal decline.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: administer every 6-12 hours; Cr Cl <10 m L/min: administer every 12-24 hours; maximum 2 g/day.
None
Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients on penicillin therapy. Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents.
Serious hypersensitivity reactions (anaphylaxis) can occur,Clostridium difficile-associated diarrhea (CDAD) risk,Hepatic dysfunction, including hepatitis and cholestatic jaundice, especially in elderly and patients with prior therapy,Renal impairment requires dose adjustment,Potential for superinfection with prolonged therapy
Serious hypersensitivity reactions (anaphylaxis) requiring emergency treatment,Clostridium difficile-associated diarrhea (CDAD) may occur,Prolonged use may result in superinfection with non-susceptible organisms,Use with caution in patients with renal impairment (dose adjustment needed),Skin rash is common in patients with mononucleosis or concurrent allopurinol use
History of hypersensitivity reaction to any penicillin,History of cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate,Infectious mononucleosis (risk of erythematous rash)
Hypersensitivity to ampicillin or any penicillin,Hypersensitivity to cephalosporins (cross-allergenicity possible),Infections caused by penicillinase-producing bacteria (including methicillin-resistant Staphylococci)
May be taken with food to reduce GI irritation. No significant food interactions. Avoid high-fat meals if taking extended-release formulation (fat increases absorption variability).
Food decreases absorption of oral ampicillin; take on an empty stomach. No specific food restrictions aside from timing. Avoid alcohol as it may increase gastrointestinal irritation.
FDA Category B. No evidence of teratogenicity in animal studies; human data do not indicate increased risk of major birth defects. However, use only when clearly needed in pregnancy, especially during first trimester. Theoretical risk of neonatal kernicterus if used near term due to bilirubin displacement from albumin.
Ampicillin is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. In humans, ample data across all trimesters indicate no increased risk of major birth defects, though there is a theoretical risk of altered gut flora and maternal-fetal effects from high doses. No documented teratogenicity from controlled studies in pregnant women.
Compatible with breastfeeding. Excreted into breast milk in low amounts (M/P ratio not established; amoxicillin milk concentration ~ 0.5-1% of maternal serum). No adverse effects reported in nursing infants. Consider monitoring for diarrhea or rash.
Ampicillin is excreted in breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.2–0.3. Amount ingested by the infant is estimated to be <0.1% of a therapeutic neonatal dose. The American Academy of Pediatrics considers it compatible with breastfeeding. Monitor infant for potential diarrhea, rash, or candidiasis.
No routine dose adjustment in pregnancy despite increased renal clearance and expanded plasma volume. Standard adult dosing is appropriate unless GFR <30 m L/min. Monitor for therapeutic efficacy in pregnancy-related infections (e.g., UTIs, chorioamnionitis).
Pregnancy increases renal clearance and volume of distribution for ampicillin, potentially lowering serum concentrations. For standard infections, no dose adjustment is routinely needed. However, for serious infections (e.g., meningitis, endocarditis), higher doses or more frequent intervals may be required to achieve therapeutic levels. Consider therapeutic drug monitoring in severe cases.
Administer with food to reduce GI upset. Monitor for rash, especially in patients with mononucleosis (EBV). Dose adjustment required for Cr Cl <30 m L/min. High dose (2000 mg amoxicillin) provides adequate coverage for penicillin-resistant S. pneumoniae. Avoid in penicillin allergy; cross-reactivity with cephalosporins is low but possible.
Ampicillin is a bactericidal antibiotic that inhibits cell wall synthesis. It is effective against Gram-positive cocci (except penicillinase-producing staphylococci) and some Gram-negative bacilli. Use with probenecid to increase serum levels. Monitor for rash, which may indicate mononucleosis. Dose adjustment required in renal impairment (Cr Cl <30 m L/min). Administer IV slowly over 10-15 minutes to avoid phlebitis.
Take with food or milk to minimize stomach upset.,Complete the full course even if you feel better.,Shake oral suspension well before each use.,Use backup contraception if on oral contraceptives.,Contact doctor if rash, watery diarrhea, or signs of liver problems (yellowing skin, dark urine).,Do not take if allergic to penicillin or cephalosporins.
Take ampicillin exactly as prescribed, even if you feel better.,Complete the full course of therapy to prevent resistance.,Take on an empty stomach (1 hour before or 2 hours after meals) for best absorption.,Oral suspension must be refrigerated; shake well before each use.,Discard any unused oral suspension after 14 days.,Report any skin rash, diarrhea, or difficulty breathing to your doctor immediately.,Do not use if you are allergic to penicillins or cephalosporins.,Avoid alcohol while on this medication to reduce risk of side effects.,May reduce the effectiveness of oral contraceptives; use additional birth control.
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
"The coadministration of ampicillin, a broad-spectrum penicillin antibiotic, with streptozocin, a nitrosourea antineoplastic agent used in pancreatic islet cell carcinoma, may reduce serum concentrations of streptozocin. This interaction is hypothesized to result from ampicillin-induced alterations in gut microbiota, leading to reduced enterohepatic recirculation of streptozocin metabolites or interference with renal tubular secretion of the active drug. Clinically, this could diminish the anticancer efficacy of streptozocin, potentially compromising tumor response."
"Ampicillin may reduce the serum concentration of Kanamycin via direct chemical inactivation in body fluids, particularly in patients with renal impairment. This interaction can lead to subtherapeutic aminoglycoside levels, potentially compromising antibacterial efficacy and promoting bacterial resistance. Clinically, this necessitates careful monitoring of Kanamycin levels and dose adjustments to maintain therapeutic effect."
"Ampicillin, a beta-lactam antibiotic, can reduce the serum concentration of plicamycin, an antineoplastic antibiotic, when co-administered. This interaction likely occurs due to ampicillin-induced alterations in gut microbiota, which may decrease the enterohepatic recirculation of plicamycin, leading to reduced systemic exposure. The resulting subtherapeutic plicamycin levels may compromise its antitumor efficacy and increase the risk of treatment failure."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Amoxicillin-Clavulanate vs Ampicillin, answered by our medical review team.
Amoxicillin-Clavulanate is a Penicillin Antibiotic + Beta-Lactamase Inhibitor that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Clavulanate is a beta-lactamase inhibitor that binds to and inactivates beta-lactamases, protecting amoxicillin from hydrolysis.. Ampicillin is a Penicillin Antibiotic that works by Ampicillin is a penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Amoxicillin-Clavulanate and Ampicillin depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Amoxicillin-Clavulanate is: 500 mg/125 mg orally every 8 hours or 875 mg/125 mg orally every 12 hours; intravenous: 1 g/0.2 g every 8 hours.. The standard adult dose of Ampicillin is: 250-500 mg orally every 6 hours; 1-2 g IV/IM every 4-6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Amoxicillin-Clavulanate and Ampicillin in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Amoxicillin-Clavulanate is classified as Category C. FDA Category B. No evidence of teratogenicity in animal studies; human data do not indicate increased risk of major birth defects. However, use only when clearly needed in pregnanc. Ampicillin is classified as Category A/B. Ampicillin is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. In humans, ample data across all trimesters indicate no increased risk of major bi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.